Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ARTFORCE

Financiado

Cerrado

Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatm...

Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE Loco-regional treatment is the mainstay of cancer cures in non small lung and head and neck cancer. For advanced stage cancer, dose intense multimodality treatment is required yet affected by substantial side effects. Our aim is t... ver más

30/09/2017

NKI AVL

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

STICHTING HET NEDERLANDS KANKER INSTITUUTANTO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-09-30 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

NKI AVL

0.00€ | Lider

N.D. | Participante

Proyectos interesantes

PGC2018-101302-B-I00

Medical Technol...

Applied Physics

41K€ Cerrado

BARB

Medical Technol...

Applied Physics

3M€ Cerrado

PDC2022-133382-I00

Medical Technol...

Applied Physics

150K€ Cerrado

SAF2008-03692

Medical Technol...

Applied Physics

139K€ Cerrado

FIS2010-17856

Medical Technol...

Applied Physics

36K€ Cerrado

PROMISE

Medical Technol...

Applied Physics

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

STICHTING HET NEDERLANDS KANKER INSTITUUTANTO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Loco-regional treatment is the mainstay of cancer cures in non small lung and head and neck cancer. For advanced stage cancer, dose intense multimodality treatment is required yet affected by substantial side effects. Our aim is to improve treatment outcome in locally advanced head and neck and lung cancer patients by: 1. Optimizing local control by introducing novel radiation techniques resulting in redistribution of the radiation dose, creating inhomogeneous dose distribution towards the most active part of the tumour instead of conventional homogenous doses. This redistribution can be performed without increase of toxicity. As recently reported radiation accidents in the US demonstrate, QA is of outmost importance for safe radiation delivery in complex treatments. To assure accurate delivery over time, we will monitor both the patient’s geometry as well as the delivered dose using image guided adaptive plan modifications and 3D in-vivo dosimetric verification. 2. Maximizing the benefit of combined modality treatment Both cisplatin and Cetuximab in combination with radiotherapy have shown to improve local control and survival but both drugs have severe side effects. As these drugs are not active in all patients, there is a large need to select patients which are sensitive to either drug. For this purpose the uptake of Cetuximab will be estimated by imaging tumour uptake with Zr89 labelled Cetuximab, while cisplatin sensitive tumours can be selected by biomarkers. This part was stopped in May 2014. This proposal will: 1 optimise efficiency by selecting patients on treatment specific tumour response predictors and tailoring radiation to most active parts of the tumour. 2 improve quality of life by withholding ineffective, toxic treatments and redistribution of dose. 3 decrease community costs by reserving expensive treatments for those who will benefit. This will be studied in randomized phase II clinical trials in top European institutes, followed by phase III trials outside this proposal.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores